A host–gut microbial amino acid co-metabolite, p-cresol glucuronide, promotes blood–brain barrier integrity in vivo. Issue 1 (2nd January 2023)

• Record Type: Journal Article
• Authors: Stachulski, Andrew V.; Knausenberger, Tobias B-A; Shah, Sita N.; Hoyles, Lesley; McArthur, Simon
• Is Part Of: Tissue barriers. Volume 11:Issue 1(2023)
• Publication Date: 2023-01-02
• Subjects: Blood–brain barrier -- gut–brain axis -- gut microbiota -- glucuronidation; Biological transport -- Periodicals; Tissues -- Periodicals; Biological Transport -- Periodicals; Tissues -- Periodicals; 571
• DOI: 10.1080/21688370.2022.2073175
• Languages: English
• ISSNs: 2168-8370

Abstract

ABSTRACT: The sequential activity of gut microbial and host processes can exert a powerful modulatory influence on dietary components, as exemplified by the metabolism of the amino acids tyrosine and phenylalanine to p -cresol by gut microbes, and then to p -cresol glucuronide (pCG) by host enzymes. Although such glucuronide conjugates are classically thought to be biologically inert, there is accumulating evidence that this may not always be the case. We investigated the activity of pCG, studying its interactions with the cerebral vasculature and the brain in vitro and in vivo . Male C57Bl/6 J mice were used to assess blood–brain barrier (BBB) permeability and whole-brain transcriptomic changes in response to pCG treatment. Effects were then further explored using the human cerebromicrovascular endothelial cell line hCMEC/D3, assessing paracellular permeability, transendothelial electrical resistance and barrier protein expression. Mice exposed to pCG showed reduced BBB permeability and significant changes in whole-brain transcriptome expression. Surprisingly, treatment of hCMEC/D3 cells with pCG had no notable effects until co-administered with bacterial lipopolysaccharide, at which point it was able to prevent the permeabilizing effects of endotoxin. Further analysis suggested that pCG acts as an antagonist at the principal lipopolysaccharide receptor TLR4. The amino acid phase II metabolic product pCG is biologically active at the BBB, antagonizing the effects of constitutively circulating lipopolysaccharide. These data add to the growing literature showing glucuronide conjugates to be more than merely metabolic waste products and highlight the complexity of gut microbe to host communication pathways underlying the gut–brain axis.